PDCD1 and cancer: Recently, immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) inhibitors, such as nivolumab and pembrolizumab, have been shown to have promising effects in the treatment of various types of cancer [1,2,3,4,5].